Promising prostate cancer drug extended to patients already improving
Disease control
ENROLLING_BY_INVITATION
This study gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694 if they are already benefiting from it in an earlier trial. About 40 participants will receive the drug for up to two more weeks after their previ…
Phase: PHASE1, PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated May 14, 2026 12:06 UTC